JFG
TSHA icon

Jefferies Financial Group’s Taysha Gene Therapies TSHA Stock Holding History

Jefferies Financial Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Sell
328,800
-150,200
-31% -$889K 0.01% 652
2026
Q1 		$2.14M Buy
479,000
+454,000
+1,816% +$2.11M 0.01% 618
2025
Q4 		$138K Sell
25,000
-2,131,642
-99% -$10.4M ﹤0.01% 1668
2025
Q3 		$7.05M Sell
2,156,642
-8,157,091
-79% -$23.1M 0.03% 283
2025
Q2 		$23.8M Buy
10,313,733
+10,068,479
+4,105% +$21.9M 0.2% 94
2025
Q1 		$341K Buy
+245,254
New +$410K ﹤0.01% 1189
2024
Q4 		– Sell
-73,857
Closed -$148K – 1861
2024
Q3 		$148K Sell
73,857
-183,837
-71% -$403K ﹤0.01% 1253
2024
Q2 		$577K Buy
257,694
+209,594
+436% +$610K 0.01% 921
2024
Q1 		$138K Buy
+48,100
New +$100K ﹤0.01% 1395

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jefferies Financial Group's TSHA Position: Q2 2026 in Review

Jefferies Financial Group reduced its Taysha Gene Therapies (TSHA) stake by 31% in Q2 2026, selling an estimated $889K and leaving 328,800 shares worth $2.24M. The position accounts for 0.01% of the portfolio, ranked #652.

Jefferies Financial Group first reported a position in TSHA in Q1 2024 and has held it in 9 quarters since. The position peaked at $23.8M in Q2 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Jefferies Financial Group held 328,800 shares of Taysha Gene Therapies worth $2.24M as of Q2 2026.
  • Jefferies Financial Group sold 150,200 Taysha Gene Therapies shares in Q2 2026, an estimated $889K.
  • Taysha Gene Therapies made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #652 holding.
  • Jefferies Financial Group first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 9 quarters since.
  • Jefferies Financial Group's Taysha Gene Therapies position peaked at $23.8M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.